KMT2A and leukemia: GSK3 inhibitors reduce the proliferation of MLL-transformed myeloid progenitors, induce p27Kip1, a cyclin-dependent kinase inhibitor, and prolong the survival of a mouse model of MLL-associated leukemia [10].